UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047417
Receipt number R000054073
Scientific Title Clinicopathological study on the pulmonary vasculopathy and cardiac dysfunction in pulmonary hypertension
Date of disclosure of the study information 2022/04/06
Last modified on 2024/04/16 15:26:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinicopathological study on the pulmonary vasculopathy and cardiac dysfunction in pulmonary hypertension

Acronym

PHYCS study

Scientific Title

Clinicopathological study on the pulmonary vasculopathy and cardiac dysfunction in pulmonary hypertension

Scientific Title:Acronym

PHYCS study

Region

Japan


Condition

Condition

pulmonary hypertension, interstitial lung disease, chronic obstructive pulmonary disease

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the histopathological features of pulmonary vascular lesions and myocardium in patients with chronic lung disease-associated pulmonary hypertension.

Basic objectives2

Others

Basic objectives -Others

Retrospective study to investigate the clinical and histopathological features of pulmonary hypertension

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Area ratio of media and intima of pulmonary muscular arteries

Key secondary outcomes

1. Luminal stenosis rate of pulmonary muscular arteries
2. Distribution density, wall thickening, and stenosis or dilation of pulmonary veins and lymph vessels; the presence and the degree, if present, of capillary lesions
3. Relationship between the degree of pulmonary vascular lesions and background lung lesions (emphysema, fibrosis, etc.)
4. The degree, if present, of pathological changes such as myocardial hypertrophy and fibrosis
5. Histological analysis on the target protein of pulmonary vasodilators in pulmonary blood vessels and myocardium
6. Relationship between the morphological findings and clinical course including the treatment response


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Those in whom the comprehensive consent for research use of specimens was obtained at the time of autopsy from the family member, and the following criteria were met
- Patient group to be studied (Lung-PH group): Those who had been diagnosed with pulmonary hypertension associated with lung disease (Lung-PH) by examinations including right heart catheterization after January 1st, 2001
- Control group 1 (Control group): Those who died after January 1st, 2001 for reasons other than overt cardiopulmonary disease, and the histopathological specimens were stored at the Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
- Control group 2 (PH group other than Lung-PH): Those who had been diagnosed with PH other than Lung-PH by examinations including right heart catheterization and/or autopsy, and the histopathological specimens were stored at Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
- Control group 3 (Lung-NoPH group): Those who had been diagnosed with lung disease without PH (interstitial lung disease, chronic obstructive pulmonary disease, etc.) by examinations including echocardiography and/or autopsy, and the histopathological specimens were stored at Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
2. When the voluntary consent to participate in this study has been obtained from legal representative(s) of the patients including close relative or when there has been no refusal for the participation to the present study.

Key exclusion criteria

Those who are judged by the principal investigator to be inappropriate as research subjects

Target sample size

17


Research contact person

Name of lead principal investigator

1st name Ichizo
Middle name
Last name Tsujino

Organization

Hokkaido University

Division name

Department of Respiratory Medicine, Faculty of Medicine

Zip code

060-8638

Address

Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido

TEL

011-706-5911

Email

itsujino@med.hokudai.ac.jp


Public contact

Name of contact person

1st name Ichizo
Middle name
Last name Tsujino

Organization

Hokkaido University

Division name

Department of Respiratory Medicine, Faculty of Medicine

Zip code

060-8638

Address

Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido

TEL

011-706-5911

Homepage URL


Email

itsujino@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University

Institute

Department

Personal name



Funding Source

Organization

Hokkaido University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Review Board for Life Science and Medical Research, Hokkaido University Hospital

Address

Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido

Tel

011-706-7636

Email

crjimu@huhp.hokudai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 04 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 09 Month 08 Day

Date of IRB

2020 Year 09 Month 16 Day

Anticipated trial start date

2020 Year 09 Month 16 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We searched for cases in which autopsy was performed after January 1, 2001, and histopathological specimens were stored at Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University (including Obihiro Kosei Hospital for the Lung-PH group), and then we selected the cases that met the selection criteria.


Management information

Registered date

2022 Year 04 Month 06 Day

Last modified on

2024 Year 04 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054073


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name